FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379535> ?p ?o ?g. }

• W4387379535 abstract "Abstract Disclosure: D.T. Papadimitriou: None. E. Dermitzaki: None. P. Christopoulos: None. M. Papagianni: None. K. Kleanthous: None. C. Marakaki: None. A. Papadimitriou: None. G. Mastorakos: None. Type 1 diabetes (T1D) hits about 1:300 with rising incidence affecting increasingly younger children. Population screening at ages 2 and 6 yrs with T1D associated autoantibodies (T1Ab) has been recently proven sensitive. While potential treatments to prevent or delay T1D are currently in development, a population based cost-effective preventive strategy is still lacking. Hence, 2000 IU cholecalciferol daily in a large birth cohort study published in 2001 reduced by 80% the risk of T1D in 1 yr. A pilot clinical trial 10 yrs ago, demonstrated negativation of T1Ab within 0.6 (0.4-2.1) yrs under oral calcitriol in 12 children. To further pursue this hypothesis, we initiated a prospective interventional non-randomized clinical trial, the PRECAL study (ISRCTN17354692). Between 2010-2022, 50 children (26 boys, 24 girls) aged 0.65-16,37 yrs identified as at high risk for T1D were included: 44 were positive for T1Ab (Insulin auto-antibodies, IAA; anti-tyrosinase abs, IA2, anti-glutamic decarboxylase abs, GAD; islet auto-abs, ICA; anti-Zn8 if available) and 6 with negative T1Abs had predisposing HLA A DQ DR haplotypes and genotypes. Nine were diagnosed with varied impaired glucose tolerance (IGT) ( all T1Ab+), 4 with pre-T1D (3 T1Ab+ and 1 HLA+), and 9 had new-onset T1D (all T1Ab+). Serum T1Ab levels and fasting plasma glucose, HbA1c, c-peptide, Ca (tolerated ≤11.5 mg/dl), P, ALP, Ca/Cr 2-hr urine morning sample, 25(OH)D, 1-25(OH)2D with renal ultrasound in cases with hypercalcemia/hypercalciuria (tolerated ≤50%, or at the upper normal for age) were determined before and q3-6 months after initiation of calcitriol (0.05 mcg/Kg/day) 0.25-0.5 x 1-3/day or its synthetic analogue, paricalcitol (thrice the calcitriol dose) 1-4 mcg x 1-3/day p.o. under cholecalciferol repletion. Measurements are given as median and range. Available data on 42 (7 dropouts, 1 follow-up &lt; 3 m). All 26 without pre-T1D/T1D followed 3.06 (0.5-10) yrs negativized T1Ab (15 IAA, 3 IA2, 4 ICA, 2 GAD, 1 IAA/GAD, 1 ICA/GAD) within 0.57 (0.32-1.3) yrs or did not progress to T1D [5 +HLA, follow-up 3 (1-4) yrs]. From 4 pre-T1D, 1 negativized T1Ab (follow-up 1 yr), 1 with +HLA did not progress to T1D (follow-up 3.3 yrs) and 2 with +T1Ab developed T1D in 6m/3yrs. Three out of 8 children with T1D at presentation progressed immediately to overt disease, 5 showed complete remission for 1 yr (1m-2yrs). Five with +T1Ab relapsed and negativized again after resuming therapy. Four (aged &lt; 3 yrs) negativized anti-TPO/TG, and 2 anti-transglutaminase-IgA. Eight presented mild hypercalciuria/hypercalcemia, resolving with dose titration/discontinuation. Calcitriol, and it’s less-calcemic analogue paricalcitol were 100% effective and reasonably safe in negativizing T1Ab in healthy children, possibly preventing the otherwise probably inevitable evolution towards clinical development of T1D, at least if started soon enough after seroconversion. Presentation: Friday, June 16, 2023" @default.
• W4387379535 created "2023-10-06" @default.
• W4387379535 creator A5003263310 @default.
• W4387379535 creator A5005234158 @default.
• W4387379535 creator A5019987474 @default.
• W4387379535 creator A5021023859 @default.
• W4387379535 creator A5045104666 @default.
• W4387379535 creator A5062707227 @default.
• W4387379535 creator A5078496594 @default.
• W4387379535 creator A5082335214 @default.
• W4387379535 date "2023-10-01" @default.
• W4387379535 modified "2023-10-16" @default.
• W4387379535 title "FRI608 Secondary Prevention Of Diabetes Type 1 With Oral Calcitriol And Analogs, The Precal Study" @default.
• W4387379535 doi "https://doi.org/10.1210/jendso/bvad114.832" @default.
• W4387379535 hasPublicationYear "2023" @default.
• W4387379535 type Work @default.
• W4387379535 citedByCount "0" @default.
• W4387379535 crossrefType "journal-article" @default.
• W4387379535 hasAuthorship W4387379535A5003263310 @default.
• W4387379535 hasAuthorship W4387379535A5005234158 @default.
• W4387379535 hasAuthorship W4387379535A5019987474 @default.
• W4387379535 hasAuthorship W4387379535A5021023859 @default.
• W4387379535 hasAuthorship W4387379535A5045104666 @default.
• W4387379535 hasAuthorship W4387379535A5062707227 @default.
• W4387379535 hasAuthorship W4387379535A5078496594 @default.
• W4387379535 hasAuthorship W4387379535A5082335214 @default.
• W4387379535 hasBestOaLocation W43873795351 @default.
• W4387379535 hasConcept C120665830 @default.
• W4387379535 hasConcept C121332964 @default.
• W4387379535 hasConcept C124490489 @default.
• W4387379535 hasConcept C126322002 @default.
• W4387379535 hasConcept C134018914 @default.
• W4387379535 hasConcept C187212893 @default.
• W4387379535 hasConcept C2776079296 @default.
• W4387379535 hasConcept C2781232474 @default.
• W4387379535 hasConcept C2908647359 @default.
• W4387379535 hasConcept C555293320 @default.
• W4387379535 hasConcept C61511704 @default.
• W4387379535 hasConcept C71924100 @default.
• W4387379535 hasConcept C99454951 @default.
• W4387379535 hasConceptScore W4387379535C120665830 @default.
• W4387379535 hasConceptScore W4387379535C121332964 @default.
• W4387379535 hasConceptScore W4387379535C124490489 @default.
• W4387379535 hasConceptScore W4387379535C126322002 @default.
• W4387379535 hasConceptScore W4387379535C134018914 @default.
• W4387379535 hasConceptScore W4387379535C187212893 @default.
• W4387379535 hasConceptScore W4387379535C2776079296 @default.
• W4387379535 hasConceptScore W4387379535C2781232474 @default.
• W4387379535 hasConceptScore W4387379535C2908647359 @default.
• W4387379535 hasConceptScore W4387379535C555293320 @default.
• W4387379535 hasConceptScore W4387379535C61511704 @default.
• W4387379535 hasConceptScore W4387379535C71924100 @default.
• W4387379535 hasConceptScore W4387379535C99454951 @default.
• W4387379535 hasIssue "Supplement_1" @default.
• W4387379535 hasLocation W43873795351 @default.
• W4387379535 hasOpenAccess W4387379535 @default.
• W4387379535 hasPrimaryLocation W43873795351 @default.
• W4387379535 hasRelatedWork W2014495075 @default.
• W4387379535 hasRelatedWork W2044214207 @default.
• W4387379535 hasRelatedWork W2053436511 @default.
• W4387379535 hasRelatedWork W2060903596 @default.
• W4387379535 hasRelatedWork W2078054424 @default.
• W4387379535 hasRelatedWork W2082328122 @default.
• W4387379535 hasRelatedWork W2092471470 @default.
• W4387379535 hasRelatedWork W2150711097 @default.
• W4387379535 hasRelatedWork W2576439659 @default.
• W4387379535 hasRelatedWork W3112893802 @default.
• W4387379535 hasVolume "7" @default.
• W4387379535 isParatext "false" @default.
• W4387379535 isRetracted "false" @default.
• W4387379535 workType "article" @default.